ZA200408456B - Motif-grafted hybrid polypeptides and uses thereof - Google Patents

Motif-grafted hybrid polypeptides and uses thereof

Info

Publication number
ZA200408456B
ZA200408456B ZA200408456A ZA200408456A ZA200408456B ZA 200408456 B ZA200408456 B ZA 200408456B ZA 200408456 A ZA200408456 A ZA 200408456A ZA 200408456 A ZA200408456 A ZA 200408456A ZA 200408456 B ZA200408456 B ZA 200408456B
Authority
ZA
South Africa
Prior art keywords
hybrid polypeptides
motif
grafted hybrid
diseases
hybrid
Prior art date
Application number
ZA200408456A
Other languages
English (en)
Inventor
Dennis R Burton
Moroncini Gianluca
Anthony R Wiilliamson
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of ZA200408456B publication Critical patent/ZA200408456B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • AIDS & HIV (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200408456A 2002-04-09 2004-10-19 Motif-grafted hybrid polypeptides and uses thereof ZA200408456B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37161002P 2002-04-09 2002-04-09

Publications (1)

Publication Number Publication Date
ZA200408456B true ZA200408456B (en) 2008-12-31

Family

ID=28792056

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200408456A ZA200408456B (en) 2002-04-09 2004-10-19 Motif-grafted hybrid polypeptides and uses thereof

Country Status (9)

Country Link
US (2) US7939641B2 (xx)
EP (2) EP2301959A3 (xx)
JP (3) JP4421900B2 (xx)
AT (1) ATE544780T1 (xx)
CA (1) CA2481437A1 (xx)
ES (1) ES2380925T3 (xx)
NZ (1) NZ536054A (xx)
WO (1) WO2003085086A2 (xx)
ZA (1) ZA200408456B (xx)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4235544B2 (ja) 2001-05-31 2009-03-11 アドライフ インコーポレーティッド 欠陥折畳み蛋白質センサー方法
US20050026165A1 (en) 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
WO2003085086A2 (en) 2002-04-09 2003-10-16 The Scripps Research Institute Motif-grafted hybrid polypeptides and uses thereof
CA2535261C (en) 2003-08-13 2015-11-24 Chiron Corporation Prion-specific peptide reagents
US20060035242A1 (en) 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
US20060057671A1 (en) * 2004-09-10 2006-03-16 Orser Cindy S Immobilized probes and methods of detecting conformationally altered prion proteins
WO2006064819A1 (ja) * 2004-12-14 2006-06-22 High Energy Accelerator Research Organization 中性子散乱法を用いたタンパク質の形態変化に起因する疾患の診断方法
EP1848830A4 (en) * 2005-01-13 2009-05-06 Novartis Vaccines & Diagnostic ISOLATION OF PATHOGENIC PRIONS
WO2006076683A2 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Isolation and detection of pathogenic prions
MX2007008497A (es) * 2005-01-13 2007-09-14 Novartis Vaccines & Diagnostic Ensayos inmunosorbentes enlazados a enzimas usando reactivos de peptidos especificos de prion.
AU2006214463B2 (en) * 2005-02-15 2012-08-30 Presympto, Inc. Method for detecting misfolded proteins and prions
US9335331B2 (en) * 2005-04-11 2016-05-10 Cornell Research Foundation, Inc. Multiplexed biomarkers for monitoring the Alzheimer's disease state of a subject
DE102005031429A1 (de) * 2005-07-04 2007-01-11 Heinrich-Heine-Universität Düsseldorf Verfahren zur selektiven Bestimmung pathologischer Proteinablagerungen
NZ594844A (en) 2005-09-09 2013-04-26 Novartis Ag Prion-specific peptoid reagents
CN101802609A (zh) * 2006-07-28 2010-08-11 阿德利夫股份有限公司 用于诊断和治疗的肽探针
WO2009015091A1 (en) * 2007-07-20 2009-01-29 The Government of the United States of America as represented by the Secretary of the Detection of infectious prion protein by seeded conversion of recombinant prion protein
BRPI0910550A2 (pt) * 2008-04-30 2015-09-29 Novartis Ag ensaio para confôrmeros patogênicos
CA2862979A1 (en) * 2012-01-09 2013-07-18 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
WO2013106485A2 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
US10391068B2 (en) 2012-08-06 2019-08-27 Trustees Of Boston University Prion protein ligands as therapeutic agents for neurodegenerative disorders
EP2943512A4 (en) 2013-01-11 2016-06-01 California Inst Biomedical Res FUSION BOVINE ANTIBODIES
EP3022221B1 (en) * 2013-07-18 2021-09-15 Taurus Biosciences, LLC Humanized antibodies with ultralong complementarity determining regions
BR112017005730B1 (pt) 2014-09-26 2023-12-12 Somalogic Operating Co., Inc Método para triagem de um indivíduo quanto ao risco de um evento cardiovascular ou para predizer a probabilidade que um indivíduo tenha tal evento
BR112018010937A2 (pt) 2015-12-04 2018-12-04 Novartis Ag composições de anticorpos enxertados com citocina e métodos de uso para imunorregulação
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
PE20200303A1 (es) 2017-05-24 2020-02-06 Novartis Ag Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer
US20240189456A1 (en) * 2022-12-12 2024-06-13 Regeneron Pharmaceuticals, Inc. Treatment Of Prion Diseases

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US14455A (en) * 1856-03-18 Arrangement of rotary planibtg-ketives
US87502A (en) * 1869-03-02 Alexander lee
US18674A (en) * 1857-11-24 John bryan
US1061A (en) * 1839-01-08 Improvement in the mode of evaporating liquids
US114360A (en) * 1871-05-02 Improvement in grocers canisters
US4006117A (en) * 1973-01-24 1977-02-01 Hooker Chemicals & Plastics Corporation Amine phosphite antioxidants
US3843443A (en) * 1973-03-30 1974-10-22 J Fishman Polypeptide materials bound to fluorocarbon polymers
US4244721A (en) * 1979-01-31 1981-01-13 Pedro Buarque De Macedo Method of making composite borosilicate glass articles
US4507230A (en) 1982-05-12 1985-03-26 Research Corporation Peptide synthesis reagents and method of use
US4952496A (en) * 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4778767A (en) 1984-12-17 1988-10-18 Akzo N.V. Solid phase immunoassay using immunoreagents immobilized on inert synthetic resin surfaces
DE3500180A1 (de) * 1985-01-04 1986-07-10 Ernst Prof. Dr. 7400 Tübingen Bayer Pfropfcopolymerisate aus vernetzten polymeren und polyoxyethylen, verfahren zu ihrer herstellung und ihre verwendung
US5292814A (en) * 1987-04-29 1994-03-08 Ernst Bayer Process for the preparation of monodispersed polymer beads
DE69023900D1 (de) * 1989-02-24 1996-01-11 Univ California Gentechnologisch veränderte immunglobuline.
US5306812A (en) * 1989-09-08 1994-04-26 The Regents Of The University Of California Immunoglobulin-binding polypeptides
US5231167A (en) * 1989-09-08 1993-07-27 The Regents Of The University Of California Immunoglobulin-binding polypeptides
CA2099574A1 (en) * 1991-01-04 1992-07-05 Noubar B. Afeyan Sulfonamide bonded hydrophilic coatings
NZ246059A (en) 1991-12-03 1995-08-28 Proteus Molecular Design Synthetic polypeptides with at least one antigenic site of a prion protein, methods of their use and manufacture, antibodies thereto, compositions and kits
TW327194B (en) * 1992-05-01 1998-02-21 American Cyanamid Co Novel amyloid precursor proteins and methods of using same
US5652138A (en) * 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
WO1994018221A1 (en) * 1993-02-02 1994-08-18 The Scripps Research Institute Methods for producing polypeptide binding sites
CA2115900A1 (en) * 1993-02-22 1994-08-23 Gerald W. Becker Pharmaceutical screens and antibodies
US5908969A (en) * 1994-05-13 1999-06-01 The Regents Of The University Of California Method of detecting prions in a sample and transgenic animal used for same
US5565186A (en) * 1994-05-13 1996-10-15 The Regents Of The University Of California Method of detecting prions in a sample and transgenic animal used for same
US5792901A (en) 1994-05-13 1998-08-11 The Regents Of The University Of California Detecting prions in a sample and prion preparation and transgenic animal used for same
US6168776B1 (en) * 1994-07-19 2001-01-02 University Of Pittsburgh Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
US6376170B1 (en) * 1994-10-03 2002-04-23 The Scripps Research Institute Ligand capture-directed selection of antibody
US5639581A (en) 1994-10-24 1997-06-17 Fuji Xerox Co., Ltd. Charge transporting polymer, process for producing the same, and organic electronic device containing the same
US5568762A (en) 1995-04-12 1996-10-29 Caterpillar Inc. Stabilizing device for variable displacement axial piston pumps
ES2218598T3 (es) 1995-09-14 2004-11-16 The Regents Of The University Of California Anticuerpo especifico del prpsc natural.
US5750361A (en) * 1995-11-02 1998-05-12 The Regents Of The University Of California Formation and use of prion protein (PRP) complexes
CA2251464A1 (en) * 1996-04-03 1997-10-16 Pepresearch A/S Non-dendritic backbone peptide carrier
US6451541B1 (en) * 1996-05-14 2002-09-17 Ernst-Ludwig Winnacker Chaperones capable of binding to prion proteins and distinguishing the isoforms PrPc and PrPsc
AU3186397A (en) 1996-05-29 1998-01-05 Mcgill University Prion protein binding proteins and uses thereof
WO1998030229A1 (en) * 1997-01-10 1998-07-16 Massachusetts Institute Of Technology TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE BY β-AMYLOID PEPTIDES
US20010001061A1 (en) * 1997-02-21 2001-05-10 Prusiner Stanley B. Assay for disease related conformation of a protein
US5891641A (en) * 1997-02-21 1999-04-06 The Regents Of The University Of California Assay for disease related conformation of a protein
US5962669A (en) * 1997-06-02 1999-10-05 The Regents Of The University Of California Nucleic acid encoding prion protein variant
ATE223058T1 (de) * 1997-09-19 2002-09-15 Evotec Ag Verfahren zur messung der assoziation von teilstrukturen pathologischer proteinablagerungen
DE19741607A1 (de) * 1997-09-20 1999-03-25 Prionics Ag Synthetische Polypeptide zur Diagnose und Therapie von Prionerkrankungen
US6214565B1 (en) * 1998-10-09 2001-04-10 The Regents Of The University Of California Assay for disease related conformation of a protein and isolating same
JP2002521004A (ja) * 1998-07-10 2002-07-16 キュラゲン コーポレイション ヒトβアミドイド前駆体タンパク質（β−ＡＰＰ）のヒトＬＯＮプロテアーゼ様タンパク質（ＨｓＬＯＮ）との相互作用
US6492497B1 (en) * 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
US6277970B1 (en) 1999-05-11 2001-08-21 The Regents Of The University Of California PRP-like gene
EP1187920A2 (en) 1999-06-09 2002-03-20 Arch Development Corporation Recombinant prion-like genes and proteins and materials and methods comprising same
ES2278617T3 (es) 1999-06-23 2007-08-16 Idexx Laboratories Inc Peptidos de proteinas de prion y sus usos.
WO2001087911A1 (en) 2000-05-16 2001-11-22 The Regents Of The University Of California Method of identifying critical points within protein-protein interactions
IL148202A0 (en) * 2000-06-20 2002-09-12 Caprion Pharmaceuticals Inc Copolymers and methods of treating prion-related diseases
US6505025B2 (en) 2000-06-22 2003-01-07 Kyocera Corporation Color image forming apparatus and process
US6537548B1 (en) * 2000-07-27 2003-03-25 The Regents Of The University Of California Antibodies specific for ungulate PrP
US6721761B2 (en) * 2000-12-20 2004-04-13 American Management Systems, Inc. System for assigning digital identifiers to telephone numbers and IP numbers
WO2003085086A2 (en) 2002-04-09 2003-10-16 The Scripps Research Institute Motif-grafted hybrid polypeptides and uses thereof

Also Published As

Publication number Publication date
EP1572937B1 (en) 2012-02-08
US20110250630A1 (en) 2011-10-13
AU2003231995A1 (en) 2003-10-20
ATE544780T1 (de) 2012-02-15
WO2003085086A3 (en) 2006-07-27
JP2012010704A (ja) 2012-01-19
EP2301959A2 (en) 2011-03-30
CA2481437A1 (en) 2003-10-16
EP2301959A3 (en) 2013-03-13
JP4421900B2 (ja) 2010-02-24
US7939641B2 (en) 2011-05-10
NZ536054A (en) 2009-10-30
WO2003085086A2 (en) 2003-10-16
EP1572937A2 (en) 2005-09-14
JP2005522197A (ja) 2005-07-28
US20030215880A1 (en) 2003-11-20
WO2003085086A9 (en) 2004-02-05
EP1572937A4 (en) 2007-08-08
JP2009142285A (ja) 2009-07-02
ES2380925T3 (es) 2012-05-21

Similar Documents

Publication Publication Date Title
ZA200408456B (en) Motif-grafted hybrid polypeptides and uses thereof
ATE483472T1 (de) Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
DE60032486D1 (de) Prion protein peptide und deren verwendung
MX2007013626A (es) Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos.
MX2007008017A (es) Polipeptidos que se ligan a br3 y usos de los mismos.
ATE382053T1 (de) System zur antikörperexpression und- synthese
WO2004078777A3 (en) Dipeptidyl-peptidase protected proteins
EA200001023A1 (ru) Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью
RU2013110876A (ru) Активируемые биспецифические антитела
MXPA05007853A (es) Antagonistas de il-1 beta humana.
MX2007001345A (es) Regiones variantes fc.
CY1113630T1 (el) Αντισωματα αντι-χεπσιδινης και χρησεις εξ αυτωn
PL378566A1 (pl) Ligandy dla białek wiążących TGF-beta i ich zastosowania
WO2004029072A3 (en) PrPsc -INTERACTING MOLECULES AND USES THEREOF
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
DK1572745T3 (da) Antistof anti-humant NogoA og dets farmaceutiske anvendelse
EP2292666A3 (en) Neoplasm specific antibodies and uses thereof
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
ATE358136T1 (de) Prionen-bindende peptidsequenzen
DE60229924D1 (de) Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten
AU2003261102A1 (en) Novel polynucleotide and polypeptide sequences and uses thereof
ATE528392T1 (de) Neues protein und dessen dns
WO2006076683A3 (en) Isolation and detection of pathogenic prions
WO2003083099A3 (en) Purified polypeptides involved in protein synthesis and modification
TW200718711A (en) Polypeptides that bind BR3 and uses thereof